Deliver Your News to the World

Drug-Coated Stents, An Increasing Health Concern


WEBWIRE

Buffalo, New York (February 2, 2007)

There remains concern and fear among the approximate 4 million patients throughout the United States who have received drug coated stents.

Recent studies suggest that drug-coated stents may result in late stent thrombosis (blood-clotting and blockage), which can lead to new heart attacks and death.

Many physicians now recommend patients continue taking Plavix for at least a year and perhaps indefinitely. Anyone who received a stent in the past two years should contact their doctor to discuss whether they should start or continue taking the anti-blood clotting medication, Plavix.

Doctors are now required to discuss the need to take Plavix and the duration which they will have to take Plavix, prior to a stent procedure. Some physicians are recommending that bare metal stents be used in place of the drug-coated stents.

It’s worth mentioning that although many doctors believe that Plavix use is the safest course of action, Plavix carries its own risks, including potential for internal bleeding. Long-term Plavix use and its safety in stent patients has yet to be determined and will need to be monitored over time.

Attorney Brian Goldstein states “Our clients have suffered unnecessary injuries as a result of drug-coated stents, which were supposedly designed to prevent the heart attacks and blood clots they are causing. We hope that prolonged Plavix use will prevent others from being injured”. Goldstein is an attorney who is a former Board Certified Surgeon and also heads up the mass tort department at The Barnes Firm.

The Barnes Firm currently represents individuals who have suffered serious injuries related to drug-coated stents. If you would like more information, please visit The Barnes Firm website at www.TheBarnesFirm.com and go to Practice Areas, Defective Products. If you have suffered an injury from a Drug Coated Stent, please call attorney Brian Goldstein at 1 800-483-2050.



WebWireID27041





This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.